SELLAS Life Sciences Group, Inc. Uncategorized Contracts & Agreements
71 Contracts & Agreements
- Letter Agreement, effective October 3, 2024, by and between SELLAS Life Sciences Group, Inc. and Times Square Tower Associates LLC (Filed With SEC on October 4, 2024)
- Form of Placement Agent Agreement (Filed With SEC on August 1, 2024)
- Form of Placement Agent Agreement (Filed With SEC on March 15, 2024)
- Form of Placement Agent Agreement (Filed With SEC on January 8, 2024)
- Form of Placement Agent Agreement (Filed With SEC on October 31, 2023)
- Addendum to the Side Letter Agreement dated May 24, 2023 by and between the Registrant and 3DMedicines Inc (Filed With SEC on August 10, 2023)
- Side Letter Agreement, dated December 5, 2022, by and between the Registrant and 3D Medicines Inc (Filed With SEC on March 16, 2023)
- Form of Placement Agent Agreement (Filed With SEC on December 14, 2020)
- Description of Securities (Filed With SEC on March 13, 2020)
- Form of Placement Agent Agreement (Filed With SEC on January 10, 2020)
- Form of Investor Agreement (Filed With SEC on July 9, 2019)
- Surrender Agreement made as of May 19, 2018 by and between the Registrant and Madison Avenue Suites LLC (Filed With SEC on May 24, 2018)
- Form of Side Letter dated April 30, 2018 (Filed With SEC on May 2, 2018)
- Form of Lock-Up Agreement (Filed With SEC on March 12, 2018)
- Engagement Letter dated January 16, 2018, between SELLAS Life Sciences Group, Inc. and Cantor Fitzgerald & Co (Filed With SEC on March 12, 2018)
- Form of Indemnity Agreement between the Registrant and each of its directors and executive officers (Filed With SEC on January 5, 2018)
- CONSENT (Filed With SEC on August 8, 2017)
- SUPPORT AGREEMENT (Filed With SEC on August 8, 2017)
- SUPPORT AGREEMENT (Filed With SEC on August 8, 2017)
- Amendment Agreement (Filed With SEC on July 11, 2017)
- (This space is intentionally left blank.) (Filed With SEC on May 10, 2017)
- (This space is intentionally left blank) (Filed With SEC on May 10, 2017)
- (This space is intentionally left blank) (Filed With SEC on May 10, 2017)
- (This space intentionally left blank.) (Filed With SEC on May 10, 2017)
- Attn: General Counsel (Filed With SEC on May 10, 2017)
- Amendment Agreement (Filed With SEC on May 2, 2017)
- Galena Biopharma, Inc. 2000 Crow Canyon Place Suite 380 San Ramon, California 94583 (Filed With SEC on November 9, 2016)
- Second Amendment to Offer Letter between Galena Biopharma, Inc. and Thomas J. Knapp (Filed With SEC on October 6, 2016)
- AMENDMENT AGREEMENT (Filed With SEC on August 23, 2016)
- ARTICLE I. DEFINITIONS (Filed With SEC on May 10, 2016)
- EXECUTION VERSION (Filed With SEC on May 10, 2016)
- EXECUTION VERSION (Filed With SEC on May 10, 2016)
- Galena Letterhead 4640 S.W. Macadam Avenue Suite 270 Portland, Oregon 97239 __, 2014 (Filed With SEC on March 10, 2016)
- Amendment to Offer Letter between Galena Biopharma, Inc. and Thomas J. Knapp (Filed With SEC on March 10, 2016)
- * * * * * * (Filed With SEC on August 6, 2015)
- R E C I T A L S (Filed With SEC on August 6, 2015)
- SEVENTH AMENDMENT AGREEMENT (Filed With SEC on May 14, 2012)
- SIXTH OMNIBUS AMENDMENT (Filed With SEC on May 14, 2012)
- FIFTH OMNIBUS AMENDMENT (Filed With SEC on May 14, 2012)
- FOURTH OMNIBUS AMENDMENT (Filed With SEC on May 14, 2012)
